Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Cabozantinib bij jodium-refractair gedifferentieerd schildkliercarcinoom: COSMIC-311
aug 2021 | Hoofd-halsoncologie